Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 3 (1)

Trial Status

Recruiting3

Clinical Trials (3)

Showing 3 of 3 trials
NCT05503264Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

NCT07158229RecruitingPrimary

Long-term Impact of NMDAR Encephalitis, Level 3

NCT07133113RecruitingPrimary

Medium-term Effects of Treatments in Autoimmune Encephalitis

Showing all 3 trials

Research Network

Activity Timeline